FIS1 and acute myeloid leukemia: A research conducted by Abo Elwafa et al. indicated that FIS1 was significantly overexpressed in the bone marrow of acute myeloid leukemia (AML) patients, and that high FIS1 levels showed a significant negative impact on complete remission response after therapy [73].